RightAnswer Knowledge Solutions Search Results for 7261-97-4

New Search  |  Search Results (7261-97-4)  |  Index of Example Chemical Results Pages
register now
RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.

A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
  • Chemical Identification
  • Environmental Hazards
  • First Aid/Medical Treatment
  • Handling/Storage/Shipping/Waste Management
  • Personal Protection
  • Physical Hazards/Corrective Response Actions
  • Physical/Chemical Properties
  • Regulatory/Standards/Labels
  • Report Abstracts and Studies
  • Reproductive Risk
  • Toxicology/Health Hazards/Exposure
Example of Acute Exposure data from MEDITEXT.

RightAnswer Proprietary Data Sources:

HAZARDTEXT™ Documentshelp
MEDITEXT® Documentshelp

All Other Data Sources:

HSDB® Data Bankhelp
LOLI® Listingshelp
REPROTOX® Documentshelp
RTECS® Registryhelp
Shepard's Cataloghelp
MSDSonline®help

ChemID External Links:

Other Government Links Searched via RegsKnowledge:

State Environmental Regulationshelp
CFR Regulationshelp

Example Content from MEDITEXT for 7261-97-4:


Please note: this is an extract of information from a larger document. Full document and details are available by subscription.

ACUTE EXPOSURE INFORMATION

  1. WITH THERAPEUTIC USE
    1. The most frequently occurring adverse effects following dantrolene therapy include drowsiness, dizziness, weakness, fatigue, and diarrhea. Other adverse effects that may occur following therapeutic administration of dantrolene include pericarditis, pleural effusion with peripheral and pleural eosinophilia, nausea, vomiting, abdominal pain, bowel obstruction, and rarely, hallucinations. Aplastic anemia, leukopenia, and heart failure have occurred with oral use .
    1. Fatal and non-fatal hepatitis have been reported with prolonged dantrolene therapy. Fatalities appear to be associated with the following factors: patient age over 30 years, duration of use over 2 months, female gender, higher daily doses (300 mg or more), concomitant drugs and disease, and higher bilirubin levels.
  1. WITH POISONING/EXPOSURE
    1. Dantrolene overdose data are limited. Muscular weakness, lethargy, coma, vomiting, diarrhea, and crystalluria may occur in the event of an overdose.
© 2011-2025 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.